Camosunate Paediatric Below 1Year

Camosunate Paediatric is an oral antimalarial medication containing two active ingredients in powder form: Amodiaquine base (75 mg) and Artesunate (25 mg). It is an Artemisinin-based Combination Therapy (ACT) specifically formulated for infants and toddlers below 1 year of age. It is primarily used for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite.

As an ACT, it works through a dual mechanism: Artesunate quickly reduces the number of parasites in the blood during the initial phase of treatment, while Amodiaquine, a longer-acting medication, ensures the elimination of remaining parasites. This combination is designed to provide rapid clinical relief and help prevent the development of drug resistance.

Key Benefits:

– Targeted Paediatric Formulation (Below 1 Year)

– Effective ACT Combination for Infants

– Rapid Parasite Clearance

– Convenient Powder Form for Oral Use

CAUTION: This medication must be administered exactly as directed by a healthcare professional. It is critical to complete the full course of treatment to prevent malaria from returning. Side effects in infants may include gastrointestinal upset or lethargy. Seek immediate medical care if the child’s condition does not improve, if they cannot keep fluids down, or if they develop a severe rash.